



Ad hoc announcement pursuant to Art. 53 SIX Listing Rules

## **Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB)**

**Milan, Italy – October 18, 2021, 5:45 pm CEST** - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received Tranche 5 under its financing agreement with the European Investment Bank (EIB) that was signed in October 2018 and comprises up to EUR 40 million, subject to achieving a set of agreed performance criteria. The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment plan for Europe. Tranche 5 consists of EUR 7.5 million and will primarily be used to support the Company’s development programs in diseases of the central nervous system. The first four tranches of the loan, totaling EUR 32.5 million, were received by Newron in 2019, 2020 and in September 2021.

In connection with Tranche 5, EIB has received warrants entitling it to purchase up to 151,344 ordinary shares of Newron at an exercise price of EUR 9.25 per share.

### **About Newron Pharmaceuticals**

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Brazil, Colombia, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: [www.newron.com](http://www.newron.com)

### **For more information**

#### **Newron**

Stefan Weber – CEO, +39 02 6103 46 26, [pr@newron.com](mailto:pr@newron.com)

#### **UK/Europe**

Simon Conway/ Natalie Garland-Collins, FTI Consulting, +44 (0)20 3727 1000, [SCnewron@fticonsulting.com](mailto:SCnewron@fticonsulting.com)

#### **Switzerland**

Valentin Handschin, IRF Reputation, +41 43 244 81 54, [handschin@irf-reputation.ch](mailto:handschin@irf-reputation.ch)

#### **Germany/Europe**

Anne Hennecke/Caroline Bergmann, MC Services, +49 211 52925220, [newron@mc-services.eu](mailto:newron@mc-services.eu)

#### **USA**

Paul Sagan, LaVoieHealthScience, +1 617 374 8800, Ext. 112, [psagan@lavoiehealthscience.com](mailto:psagan@lavoiehealthscience.com)